• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.66
▼ -0.01 (-0.60%)

This chart shows the closing price for ADXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Advaxis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADXS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Advaxis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.66.

This chart shows the closing price for ADXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Advaxis. This rating has held steady since April 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/19/2021Alliance Global PartnersLower TargetBuy$5.00 ➝ $2.25
6/12/2019HC WainwrightReiterated RatingHold ➝ Neutral
4/5/2019HC WainwrightSet TargetHold$4.00
1/16/2019HC WainwrightReiterated RatingHold
12/18/2018HC WainwrightDowngradeBuy ➝ Neutral
11/6/2018HC WainwrightSet TargetBuy$2.00
9/12/2018HC WainwrightReiterated RatingBuy
6/13/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$9.00 ➝ $2.00
6/8/2018HC WainwrightReiterated RatingBuy$3.00
4/17/2018HC WainwrightReiterated RatingBuy$6.00
3/14/2018HC WainwrightSet TargetBuy ➝ Buy$23.00 ➝ $6.00
3/13/2018Cantor FitzgeraldLower TargetHold ➝ Overweight$19.00 ➝ $5.00
12/28/2017Cantor FitzgeraldSet TargetBuy$19.00
12/27/2017HC WainwrightSet TargetBuy$23.00
12/22/2017Cantor FitzgeraldSet TargetBuy$19.00
(Data available from 12/4/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
6/7/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/5/2022
  • 0 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/5/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Advaxis logo
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Read More

Today's Range

Now: $1.66
Low: $1.66
High: $1.66

50 Day Range

MA: $1.89
Low: $1.58
High: $2.34

52 Week Range

Now: $1.66
Low: $1.02
High: $30.56

Volume

311 shs

Average Volume

5,568 shs

Market Capitalization

$3.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Advaxis?

The following equities research analysts have issued stock ratings on Advaxis in the last twelve months: StockNews.com.
View the latest analyst ratings for ADXS.

What is the current price target for Advaxis?

0 Wall Street analysts have set twelve-month price targets for Advaxis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Advaxis in the next year.
View the latest price targets for ADXS.

What is the current consensus analyst rating for Advaxis?

Advaxis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADXS.

What other companies compete with Advaxis?

How do I contact Advaxis' investor relations team?

Advaxis' physical mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company's listed phone number is (609) 452-9813 and its investor relations email address is [email protected] The official website for Advaxis is www.advaxis.com. Learn More about contacing Advaxis investor relations.